Literature DB >> 9097986

Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth.

N Carbó1, J López-Soriano, T Tarragó, O González, M Llovera, F J López-Soriano, J M Argilés.   

Abstract

The implantation of the Yoshida AH-130 ascites hepatoma (a fast growing tumour) to rats resulted in a dramatic loss of both white adipose tissue and muscle (skeletal and cardiac) mass. Administration of beta2-adrenergic agonists to tumour-bearing rats resulted in a partial recovery of skeletal muscle and heart mass. Treatment of the tumour-bearing animals with the different drugs (salbutamol, salmeterol and clenbuterol) did not influence tumour growth or food intake so it can be suggested that the effects were solely due to metabolic changes. In addition, while the three drugs had clear effects on gastrocnemius muscles, clenbuterol and salbutamol had also an effect on soleus, and salbutamol had a clear effect on cardiac muscle. It is suggested that any of the studied beta2-adrenergic agonists (but perhaps, particularly salmeterol) could be used clinically in the treatment of cancer cachexia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097986     DOI: 10.1016/s0304-3835(97)04718-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

Review 1.  Managing cancer-related anorexia/cachexia.

Authors:  G Mantovani; A Macciò; E Massa; C Madeddu
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Failure-to-thrive syndrome associated with tumor formation by Madin-Darby canine kidney cells in newborn nude mice.

Authors:  Lauren R Brinster; Romelda L Omeir; Gideon S Foseh; Juliete N Macauley; Philip J Snoy; Joel J Beren; Belete Teferedegne; Keith Peden; Andrew M Lewis
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

Review 3.  A review of the drug treatment of cachexia associated with cancer.

Authors:  B Gagnon; E Bruera
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 4.  Muscle alterations in the development and progression of cancer-induced muscle atrophy: a review.

Authors:  Megan E Rosa-Caldwell; Dennis K Fix; Tyrone A Washington; Nicholas P Greene
Journal:  J Appl Physiol (1985)       Date:  2019-11-14

5.  Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice.

Authors:  Sean R Jesinkey; Midhun C Korrapati; Kyle A Rasbach; Craig C Beeson; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2014-10-07       Impact factor: 4.030

6.  α-Ketoglutarate prevents skeletal muscle protein degradation and muscle atrophy through PHD3/ADRB2 pathway.

Authors:  Xingcai Cai; Yexian Yuan; Zhengrui Liao; Kongping Xing; Canjun Zhu; Yaqiong Xu; Lulu Yu; Lina Wang; Songbo Wang; Xiaotong Zhu; Ping Gao; Yongliang Zhang; Qingyan Jiang; Pingwen Xu; Gang Shu
Journal:  FASEB J       Date:  2017-09-22       Impact factor: 5.191

Review 7.  cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration.

Authors:  Rebecca Berdeaux; Randi Stewart
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-21       Impact factor: 4.310

8.  Animal models of anorexia and cachexia.

Authors:  Mark Daniel Deboer
Journal:  Expert Opin Drug Discov       Date:  2009-11-01       Impact factor: 6.098

Review 9.  Signaling pathways controlling skeletal muscle mass.

Authors:  Marc A Egerman; David J Glass
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-11-18       Impact factor: 8.250

10.  Beta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis.

Authors:  D P Tonge; S W Jones; T Parr; R Bardsley; M Doherty; R A Maciewicz
Journal:  Osteoarthritis Cartilage       Date:  2009-12-21       Impact factor: 6.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.